EU’s Pharma Legislative Reform
While the outcome of the US presidential election is drawing most of the political attention these days, other political activity in Europe merits serious attention as well. Pharma reform legislation is moving forward in the EU that could significantly change everything from how firms manufacture their products to how much market exclusivity they get for them. These Pink Sheet stories break down the key issues, explaining what is already basically set and what remains undecided in this major initiative.
Related product